Background Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ/TMZ). Unfortunately, no data are available concerning the predictive value of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation for this important subpopulation. For clarification, a prospective study was conducted. Methods Adult patients with a non-resectable glioblastoma were included. A molecular stereotactic biopsy technique was used for tumour characterisation combining histopathological diagnosis with small sample size adjusted methylation-specific PCR (MSP) and sodium bisulfite sequencing. Treatment included XRT (60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m 2 )/ TMZ (150e200 mg/m 2 per day for 5 days of every 28-day cycle). The primary end point was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment response (TR). Patients were categorised in the Radiation Therapy Oncology Group (RTOG)-recursive partitioning analysis (RPA) Classes III (N¼4), IV (N¼12), V (N¼28) and VI (N¼12). Results and discussion The success rates of MSP and sequence analyses were 100%. The MGMT promoter was methylated in 30/56 tumours, which was associated with an increased PFS (median 56 versus 20 weeks; hazard ratio 0.15; range 0.07 to 0.33; p<0.0001), higher frequency of TR (93.3% vs 46.2%; p¼0.0008) and increased OS (median 104 vs 28 weeks; hazard ratio 0.18; range 0.08 to 0.38; p<0.0001). The transient perioperative morbidity was 1.8%. Conclusion MGMT promoter methylation has a predominant favourable influence even for the important subpopulation with non-resectable glioblastoma. The molecular stereotactic biopsy technique is safe and effective for predictive evaluation and helps to avoid both over-and undertreatment.
INTRODUCTION
The incidence of malignant gliomas has increased over the last two decades, especially in the older subpopulation, and currently lies in the range of five cases per 100 000. 1 Glioblastoma account for approximately 60e70% of these tumours. Recently, important progress has been achieved in the treatment of this most malignant tumour. First, radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ/TMZ) has resulted in significant prolongation of both time to progression and survival as compared with XRT alone; this was demonstrated by the results of the prospective randomised trial performed by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group. 2 3 Second, epigenetic silencing of the promoter of the gene that encodes O 6 -methylguanine-DNA methyltransferase (MGMT) in tumour specimens has been identified as a favourable predictive factor of benefit from XRT/TMZ/TMZ; this was shown in a companion retrospective study. 4 The impact of these findings on clinical practice, however, is still under debate: subgroup analysis suggests that relative young and/or fit patients harbouring a tumour with a methylated MGMT promoter and undergoing resection rather than biopsy benefit most from XRT/TMZ/TMZ. 2 It remains unclear as to which extent unfavourable prognostic factors such as increased age and/or a deep seated tumour location might outweigh potential benefit resulting from MGMT methylation. 5 The important subgroup of patients with non-resectable glioblastoma is particularly concerned: patients having undergone biopsy only experienced the worst outcome in the EORTC/NCIC trial, which was irrespective of treatment 2 dhowever, no stratification by the MGMT methylation status was done, because this biomarker could not be analysed from small biopsy specimens. 4 In this situation, oncologists are confronted with unawareness and uncertainty concerning appropriate treatment strategies for those patients not suitable for open tumour resection. The current prospective study was conducted to elucidate for the first time the prognosis of patients with non-resectable glioblastoma undergoing XRT/TMZ/TMZ after adjustment for the effects of MGMT promoter methylation and other relevant prognostic factors. Characterisation of the tumour was performed using the molecular stereotactic biopsy technique which combines state-of-theart histopathological evaluation with a small sample size adjusted molecular genetic analysis. 6e8 The current study should not be regarded as an appendix to the EORTC/NCIC trial. Both studies differ in terms of selection criteria and applied treatment strategies.
METHODS Patients
Adult patients (aged 18e85 years) were eligible if they had (1) a supratentorial glioblastoma not suitable for gross total tumour resection (because of an eloquent tumour location and/or significant comorbidity) with histology being proven by stereotactic biopsy, (2) no severe mass effect of the tumour demanding debulking surgery because of brainstem compression and/or midline shift, (3) no prior history of surgery, XRT and/or chemotherapy, (4) a Karnofsky performance score (KPS) $60 9 and (5) adequate haematologic, renal and hepatic function (as being defined before). 3 All enrolled patients gave informed consent. The study protocol was approved by the institutional review board (AZ 216/14) of the Ludwig Maximilians University Munich, Germany.
Molecular stereotactic biopsy technique
The still new technique of molecular stereotactic biopsy has been described previously. 6e8 In brief, coregistration of computerised tomography (CT) and magnetic resonance imaging (MRI; including T1-and T2-weighted sequences) served for three-dimensional (3D) visualisation (i-plan stereotaxy, BrainLAB, Feldkirchen, Germany) of the tumour and the simulation of the best trajectory. Serial biopsies were taken along a trajectory representative of the solid tumour. Using microforceps, the maximum amount of tissue per biopsy specimen was 1 mm 3 . The number of specimens taken in 1 mm steps along the chosen trajectory was in the range of 10e18 samples per tumour. The tissue-sampling procedure was guided by intraoperative smear preparations, which were routinely performed by the attending neuropathologist: only tumour probes next (ie, 1 mm distance) to smear preparations exclusively showing solid vital tumour tissue were used for molecular genetic analysis; a corresponding sample (level +1 mm) was taken for paraffin embedding and histopathological examination using standard protocols. 8 Samples chosen for molecular genetic analysis were snap-frozen immediately after withdrawal. The described biopsy technique was chosen to minimise the risk of tissue contamination (eg, by nonneoplastic or necrotic tissue) and, more importantly, to recognise contamination, if it occurs. For determination of the MGMT promoter methylation status, at least two tissue samples were collected from different sites throughout each tumour to test for both the intratumoural distribution of the biomarker and the reproducibility of the molecular genetic analysis. The histological diagnosis of all tissue specimens was made according to the 2007 World Health Organization (WHO) classification of tumours of the central nervous system. 10 A CT-scan was done 1 day after biopsy in all patients, and any sequels attributed to the biopsy procedure were classified as morbidity.
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Methylation-specific PCR (and sequencing analysis)
Isolation of nucleic acids, bisulfite modification of DNA, methylation-specific PCR (MSP) and sequencing analyses were done as published previously in detail. 8 12 In brief, DNA isolation from tumour specimens was performed using the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany), and DNA recovery from each stereotactic biopsy sample amounted to around 30e60 ng/ ml. This step was followed by purification and bisulfite modification of DNA according to Mollemann et al. 12 MSP and sequencing analyses were performed using the specific primer pairs as described previously.
13e15 'Unmethylated' and 'methylated' tumours were defined according to Grasbon-Frodl et al. 8 Sequencing of bisulfite-modified DNA indicated a methylated promoter when more than half of the CpG sites (13 of 25 CpG sites) were found to be methylated; partial methylation was defined as the cytosine and thymine peaks being equally sized or the cytosine peak being twice as high as the corresponding thymine peak.
Study design
Patients were enrolled in the period from March 2006 to August 2008. Patients were categorised according to the Radiation Therapy Oncology Group (RTOG)-recursive partitioning analysis (RPA) classes. 16 The KPS was used for clinical evaluation. 9 Rating on the KPS was done independently by two investigators (NT and FWK). In case of discordantly rated performance scores, a third investigator (JCT) was introduced, and the most matching score was used thereafter. Histopathological diagnosis and determination of the MGMT methylation status were obtained within 5e7 working days. Within 3 weeks after stereotactic biopsy, patients were assigned to receive XRT/TMZ/TMZ: treatment included XRT (60 grey in 30 fractions)/TMZ [daily dose of 75 mg/m 2 ]/TMZ (150e200 mg/m 2 per day for 5 days of every 28-day cycle). In case of long-term compliance, however, TMZ was continued (at the same dose) until tumour progression occurred. At baseline evaluation, 4e6 weeks after XRT/TMZ and every three cycles during TMZ maintenance therapy, clinical and neuroradiological examinations were performed (until last follow-up). MRI interpretation was independently done according to the Macdonald criteria 17 by an experienced neuroradiologist (JL), who was blinded for the MGMT status and the follow-up data of the patient. Treatment response was evaluated after the completion of three TMZ cycles or earlier in case of clinical deterioration. Tumour progression had to be confirmed by further clinical and neuroradiological follow-up to exclude any bias by pseudoprogression. 18 Additional metabolic imaging 19 and/or stereotactic rebiopsy were considered necessary, when further (modified) invasive treatment strategies were under consideration. Haematology was performed weekly. Adverse events were defined according to the National Cancer Institute (NCI) Common Toxicity Criteria, version 3.0. The minimum follow-up after inclusion of the last patient had to be 6 months.
Statistical analysis
The hazard ratio for tumour progression was in the range of 0.48 in favour of the MGMT promoter methylated group in the study of Hegi et al. 4 In the absence of cytoreductive surgery, we expected an even more pronounced outcome difference; this assumption was indirectly supported by the study of Chinot et al, 20 who have found highly divergent outcome scores as a function of MGMT expression after neoadjuvant TMZ of non-resectable glioblastoma (median progression-free survival (PFS): 5.5 vs 1.9 months). In the current series, a hazard ratio of 0.4 or even less in favour of the MGMT promoter methylated group was expected. Assuming exponential survival, we estimated that a sample size in the range of 27 patients or more in each group would be sufficient to have a power of 80% to demonstrate a significant difference in PFS in favour of glioblastoma with a methylated MGMT promoter.
The reference point of this study was the date of the diagnosis. The primary endpoint was PFS; secondary endpoints were treatment response (TR) and overall survival (OS). PFS and OS were analysed by the KaplaneMeier method 21 and compared with the two-sided logrank test. Logistic regression models were used to analyse the association between TR and other variables. The Cox model was fitted to assess the prognostic value of the MGMT methylation status and other potential prognostic factors. 22 First, the importance of each variable was tested univariately. Second, all variables were fitted together. The 'BEST' model contained only variables associated with PFS or OS after adjustment for the effects of the other variables. The distribution of patient-and tumourrelated variables between MGMT promoter methylated and unmethylated subgroups was analysed by the c 2 statistics (for dichotomised variables) and the Wilcoxon test (for continuously scaled variables). A p value of #0.05 was considered significant. All calculations were performed using the SAS software package (version 9.1).
RESULTS

Patient characteristics
Out of an overall number of 136 patients newly diagnosed as having a glioblastoma in our department between March 2006 and August 2008, a total of 56 consecutive patients (33 men, 23 women) fulfilled inclusion criteria and were enrolled in this study. Patients were categorised into RTOG-RPA class III (four patients, 7.1%), class IV (12 patients, 21.4%), class V (28 patients, 50.0%) and class VI (12 patients, 21.4%). The median of the age distribution was 62.5 years (range 23e85 years); 22 (39%) patients were 65 years of age or older. The median KPS was 70; 24 patients (42.9%) experienced a KPS of 70, and 13 a KPS of 60 (23.2%). Forty-eight patients (85.7%) exhibited multifocal (six patients) or eloquent (42 patients) tumour locations including involvement of the primary motor/sensory cortex (10 patients), speech area (eight patients), visual cortex (three patients), basal ganglia (16 patients) and the corpus callosum (five patients). Stereotactic biopsy procedures were associated with a transient morbidity of 1.8% (one patient with transient aphasia). MSP and sequencing analyses always exhibited concordant and reproducible results throughout each tumour (mean number of samples per tumour: 3; range 2e5). The overall frequency of MGMT methylated tumours was 53.6% (30/56) including one patient with a partially methylated promoter. Methylated and unmethylated subpopulations did not differ with respect to patients' characteristics, even though patients with a methylated MGMT promoter were somewhat younger (table 1) .
One patient was lost to follow-up 24 weeks after biopsy without experiencing tumour progression at this time. Two patients had to be discontinued from concomitant TMZ after 3 and 4 weeks, respectively, because of grade 3 haematological toxicity and lung embolism. Adjuvant TMZ was not initiated in three patients because of low clinical performance (KPS<60) after XRT/TMZ, which was associated with a decline in the mental status (disorientation and confusion). TMZ maintenance therapy caused grade 1/2 toxicity in 12 patients. As a consequence of grade 3 toxicity, adjuvant TMZ had to be interrupted for 4 weeks in two patients and to be discontinued after two cycles in one patient (table 2) .
Adverse events were more often seen in older patients (median age of patients with/without adverse events: 70 versus 57.5 years; p<0.03). The application of more than six TMZ cycles (15 patients with a median number of nine TMZ cycles) was not associated with increased toxicity. However, late grade 2 haematotoxicity was seen in two patients after the 11th and 14th cycle of TMZ, respectively. MRI-based suspicion of tumour progression was additionally verified by metabolic imaging table 3 ).
The survival advantage, however, was less pronounced for those with an unmethylated MGMT promoter (median: 44 weeks vs 104 weeks, p<0.001). At the time of tumour progression, treatment concepts included second-line chemotherapy (n¼16), reirradiation (n¼4), tumour debulking due to significant space occupying effects (n¼2), stereotactic brachytherapy (n¼3), a combination of these treatment modalities (n¼8) and palliative care (n¼23). The median survival after progression was longer for methylated tumours (3.7 months versus 1.9 months); the difference, however, was not significant.
Prognostic and predictive factors
Univariately, MGMT promoter methylation, younger age, higher KPS scores and RTOG-RPA classes III+IV were positively correlated with both increased PFS and OS. In the 'BEST' prognostic Cox models, only MGMT promoter methylation status (OS: p<0.0001; PFS: p<0.0001), younger age (PFS: p¼0.02) and higher KPS scores (OS: p¼0.02) remained statistically significant (table 4) .
The adjusted hazard ratio of 0.2 (95% CI 0.09 to 0.43) of MGMT promoter methylation for PFS was consistent with the unadjusted hazard ratio of 0.15 (95% CI 0.07 to 0.33). Logistic regression analysis identified MGMT promoter methylation as the only predictor for TR (partial response or stable disease; p¼0.0008); the prognostic influence of age (which was detected in one-variable models) was lost.
DISCUSSION
Currently, patients with non-resectable glioblastoma undergoing XRT/TMZ/TMZ are left with uncertainties concerning their prognosis. Moreover, they are unlikely to be entered into randomised clinical trials, addressing molecular biomarkers such as MGMT methylation for patient stratification. Difficulties in performing molecular genetic analyses from small biopsy specimens have so far added to these barriers in knowledge and scientific evaluation. 4 Here, we show in a prospective consecutive series of 56 non-resectable glioblastoma patients that by means of the still new technique of molecular stereotactic biopsy, even this somewhat neglected patient population can be addressed: overall survival for patients of this study cohort was similarly poor as compared with those undergoing biopsy only in the EORTC/NCIC trial. 2 Outcome measurements, however, became highly divergent after stratification for MGMT promoter methylation. Whereas patients harbouring a glioblastoma with an unmethylated MGMT promoter experienced both extremely short PFS and OS, those with a methylated promoter exhibited surprisingly long PFS and OS. The time to progression was similar to that reported by Hegi et al 4 after cytoreductive surgery Figure 1 KaplaneMeier estimates of progression-free survival and overall survival among patients with glioblastoma who were diagnosed by stereotactic biopsy and prospectively treated with radiotherapy plus concomitant and adjuvant temozolomide. Figure 2 KaplaneMeier estimates of progression-free survival (A) and overall survival (B) among patients with glioblastoma stratified for the MGMT promoter methylation status who were diagnosed by stereotactic biopsy and prospectively treated with radiotherapy plus concomitant and adjuvant temozolomide. meth, methylated; unmeth, unmethylated.
plus XRT/TMZ/TMZ. Survival after tumour progression, however, was shorter in the current series. One may speculate that the relatively large tumour volumes, which were not reduced by open surgery, have led to a relatively delayed diagnosis of tumour progression (using the Macdonald criteria). 17 It should be further noted that a considerable number of patients received more than six cycles of TMZ in our series, which indicate an important difference to the EORTC/NCIC trial; accordingly, any comparative analysis should be avoided at this moment.
Early tumour progression was associated with poor outcome in all patients of this series. Apparently, pseudoprogression does not seem to be a frequent event in non-resectable glioblastoma patients undergoing XRT/TMZ. Partial response or tumour control (3 months after XRT/TMZ) was a strong predictor for a more favourable outcome and not unequivocally related to the MGMT promoter status: 93.3% of the MGMT methylated and, noteworthy, 46.2% of the unmethylated tumours exhibited partial response/stable disease after XRT/TMZ/TMZ. Survival, however, was significantly longer in case of a methylated MGMT promoter. Thus, for treatment responders with an unmethylated MGMT promoter, the benefit of XRT/ TMZ/TMZ as compared with XRT alone continues to be unclear. Future studies are required that further elucidate the molecular network of epigenetic silencing of the MGMT promoter and MGMT gene expression in correlation with clinical course and prognosis. 23 Molecular stereotactic biopsy turned out to be a safe (transient morbidity of as low as 1.8% in this series) and precise diagnostic procedure. The highly controlled sampling technique ensured the use of only vital tumour tissues for subsequent molecular analyses, and excluded bias of the results by non-neoplastic tissue contaminations. Handling of nucleic acids as well as routine setup for MSP and sequencing analyses was successfully adapted to the small tissue samples containing limited amounts of nucleic acids. 8 Due to these efforts, there were no drop-outs due to difficulties in determining the MGMT promoter status: the success rates of MSP and sequencing were 100%, and both methods exhibited 100% concordant findings throughout each tumour investigated. The latter indicates a homogenous intratumoural distribution of the biomarker. The overall frequency of tumours harbouring a methylated MGMT promoter was 53.6%, which was slightly higher than in the study by Hegi et al (MGMT promoter methylated tumours: 45%) 4 ; the difference between these studies was not statistically significant and might have occurred by chance. However, the exact assignment of each biopsy specimen within the stereotactically defined tumour space, the determination of its relation to tumour necrosis or non-neoplastic tissue by alternating histopathological and molecular evaluation within 1 mm steps, the simultaneous application of two molecular genetic methods at different sites of each tumour and the exclusive use of cryopreserved specimens indicate important differences from the study by Hegi et al. 4 We further demonstrate that the MGMT status after XRT/ TMZ/TMZ remained unchanged, which was seen in 13 patients undergoing stereotactic rebiopsy because of tumour progression. Both the detected intratumoural homogeneous distribution of the MGMT promoter methylation status and its unchanged pattern before and after XRT/TMZ/TMZ suggest that MGMT promoter methylation may be a rather early event in tumour genesis.
In summary, the current series describes for the first time the powerful treatment effects of XRT/TMZ/TMZ for patients with non-resectable glioblastoma in case of a methylated MGMT promoter. It underscores that non-resectable tumours should not be associated per se with a worse prognosis as compared with those undergoing open tumour resection. The demonstrated high diagnostic sensitivity and specificity of MSP 
